• Health technology assessment (HTA) including cost-effectiveness, cost-utilization, and cost-benefit analysis for pharmaceutical companies and medical device companies
• Economic value of drugs, including antihypertensive and anti-hyperlipidemic agents, diabetes drugs, hepatitis C drugs, antidepressants, anticancer agents, anticoagulation drugs, and drugs for COPD, hemophilia, and amyotrophic lateral sclerosis
• Economic value of bariatric surgery
• Economic value of disease management programs and screening
• Analysis on adverse drug events for hospitals
• Value-based design of health insurance, including the cost-sharing structure of diabetes drugs and chemotherapy for cancer patients
• Development of a predictive model for a disease management company in Japan
• Development of a predictive model for long-term care cost
• Development of budget impact models (BIMs) for drugs for diabetes and hepatitis C patients
• Development of benchmarks on outcomes for hospitals
• Stochastic modeling, including:
• Generalized linear model (GLM)
• Survival model
• Hierarchal Bayesian model
• Bayesian network model
• Development of healthcare reform models for accountable care organizations (ACOs)
• Development of health insurance products, disability income products, long-term care products, and critical illness products for life and health insurance companies
• Pricing and profit testing of insurance policies
• Due diligence in M&A of life/health insurance companies

He is a member of the Institute of Actuaries of Japan’s Health Insurance Committee.